Zenas BioPharma, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Emerging growth company
State of Incorporation
DE
Business Address
852 WINTER STREET, SUITE 250, WALTHAM, MA, 02451
Mailing Address
852 WINTER STREET, SUITE 250, WALTHAM, MA, 02451
Phone
857-271-2954
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
-$156.99M
Net Income
$383.64M
Total Assets
$141.50M
Total Liabilities
$319.74M
Cash & Equivalents
$-8.44
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | April 2, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | April 2, 2026 | View on SEC |
| 4 Insider stock transaction report | April 1, 2026 | View on SEC |
| 4 Insider stock transaction report | March 31, 2026 | View on SEC |
| 4 Insider stock transaction report | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| 424B5 Prospectus supplement | March 30, 2026 | View on SEC |
| 424B5 Prospectus supplement | March 30, 2026 | View on SEC |
| 424B5 Prospectus supplement | March 26, 2026 | View on SEC |
| 424B5 Prospectus supplement | March 26, 2026 | View on SEC |
Annual Reports
10-K
March 16, 2026
- Successfully advanced lead product candidate ZB001 into Phase 2b clinical trials for Systemic Lupus Erythematosus.
- Secured Orphan Drug Designation from the FDA for ZB002, offering significant benefits and de-risking its development.
Insider Trading
STRONG BUY
4 insiders
14 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.